Positive News SentimentPositive NewsNASDAQ:KLRS Kalaris Therapeutics (KLRS) Stock Price, News & Analysis $4.53 +0.46 (+11.30%) Closing price 07/1/2026 04:00 PM EasternExtended Trading$4.64 +0.11 (+2.32%) As of 07/1/2026 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kalaris Therapeutics Stock (NASDAQ:KLRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kalaris Therapeutics alerts:Sign Up Key Stats Today's Range$4.15▼$4.6050-Day Range$4.07▼$6.3352-Week Range$2.14▼$11.88Volume54,437 shsAverage Volume78,008 shsMarket Capitalization$107.77 millionP/E RatioN/ADividend YieldN/APrice Target$15.60Consensus RatingModerate Buy Company Overview Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Read More Kalaris Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreKLRS MarketRank™: Kalaris Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 88th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingKalaris Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialKalaris Therapeutics has a consensus price target of $15.60, representing about 244.4% upside from its current price of $4.53.Amount of Analyst CoverageKalaris Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kalaris Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Kalaris Therapeutics are expected to grow in the coming year, from ($2.00) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kalaris Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kalaris Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalaris Therapeutics has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.05% of the float of Kalaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverKalaris Therapeutics has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Kalaris Therapeutics has recently decreased by 4.85%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKalaris Therapeutics does not currently pay a dividend.Dividend GrowthKalaris Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentKalaris Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Kalaris Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for KLRS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Kalaris Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $1,179,969.00 in company stock, which represents 1.0949% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Kalaris Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,179,969.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders68.10% of the stock of Kalaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of Kalaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kalaris Therapeutics' insider trading history. Receive KLRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kalaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KLRS Stock News HeadlinesKalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively EnrollingJune 23, 2026 | globenewswire.comKalaris to Present at Clinical Trials at the Summit 2026June 12, 2026 | finance.yahoo.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Kalaris Therapeutics Stock Price HistoryMay 30, 2026 | investing.comKalaris Therapeutics director Akkaraju’s fund buys $1.18m stockMay 22, 2026 | investing.comKalaris Therapeutics Inc KLRSMay 16, 2026 | morningstar.comMWedbush initiates coverage of Kalaris Therapeutics (KLRS) with outperform recommendationMay 15, 2026 | msn.comKalaris Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 12, 2026 | globenewswire.comSee More Headlines KLRS Stock Analysis - Frequently Asked Questions How have KLRS shares performed this year? Kalaris Therapeutics' stock was trading at $8.44 at the start of the year. Since then, KLRS shares have decreased by 46.3% and is now trading at $4.53. How were Kalaris Therapeutics' earnings last quarter? Kalaris Therapeutics Inc. (NASDAQ:KLRS) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06. How do I buy shares of Kalaris Therapeutics? Shares of KLRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2026Today7/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 KLRS's financial health is in the Yellow zone, according to TradeSmith. KLRS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KLRS CIK1754068 WebN/A Phone(617) 433-2605FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for Kalaris Therapeutics$15.60 High Price Target$25.00 Low Price Target$3.00 Potential Upside/Downside+244.4%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($2.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-72.78% Return on Assets-43.49% Debt Debt-to-Equity RatioN/A Current Ratio12.19 Quick Ratio12.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.21 per share Price / Book1.08Miscellaneous Outstanding Shares23,790,000Free Float7,590,000Market Cap$107.77 million OptionableN/A Beta0.19 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:KLRS) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredWhat Happens to Your Assets If You Die Without a Will?Without a will, your state's intestacy laws decide how your assets are divided — a rigid formula that ignores ...SmartAsset | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
